Cogent Biosciences, Inc. (NASDAQ: COGT) reported its fourth‑quarter and full‑year 2025 financial results, showing a cash, cash equivalents and marketable securities balance of $900.8 million as of December 31, 2025, up from $287.1 million at the end of 2024. The company posted a net loss of $102.5 million for the quarter and $328.9 million for the year, compared with $67.9 million and $255.9 million respectively in 2024.
Operating cash usage in the fourth quarter totaled $38.5 million, driven largely by a $54.8 million repayment of long‑term debt and a one‑time $38.5 million performance‑based equity compensation expense. The debt repayment reflects the company’s ongoing effort to reduce leverage, while the equity expense is tied to performance metrics that were met in 2025.
Research and development expenses rose to $75.6 million in Q4, reflecting continued investment in bezuclastinib’s pivotal trials and the development of other pipeline candidates. General and administrative expenses increased to $23.9 million, a result of ramp‑up activities for commercial readiness. Together, the higher R&D and G&A costs, the debt repayment, and the equity compensation expense explain the widening net loss from $67.9 million in 2024 to $102.5 million in Q4 2025.
The company highlighted several regulatory milestones: it filed the SUMMIT NDA for bezuclastinib in non‑advanced systemic mastocytosis on December 30, 2025; it initiated the PEAK NDA under the FDA’s RTOR program for second‑line GIST, with a submission expected in April 2026; and it remains on track to submit the APEX NDA for advanced systemic mastocytosis in the first half of 2026. CEO Andrew Robbins said, "Following three positive pivotal trials in 2025, we have entered 2026 with tremendous momentum and multiple value‑creating regulatory catalysts underway." He added, "We have submitted our SUMMIT NDA for bezuclastinib in patients with NonAdvSM, initiated our PEAK NDA under the FDA's RTOR program for bezuclastinib in patients with second‑line GIST, and remain on track to submit our APEX NDA for bezuclastinib in patients with AdvSM in the first half of this year. These recent and upcoming milestones underscore the breadth of bezuclastinib's best‑in‑class potential across KIT‑mutant driven diseases."
Looking ahead, Cogent’s strong cash position provides a runway through 2028, allowing the company to continue funding its clinical programs and to build a commercial organization in preparation for a second‑half 2026 launch of bezuclastinib. In addition to bezuclastinib, the company is advancing a KRAS inhibitor (CGT6737) and a PI3Kα inhibitor (CGT6297) as part of its broader pipeline.
The results underscore Cogent’s investment‑heavy strategy, with significant cash reserves and a clear regulatory trajectory that positions the company for potential commercial success once approvals are obtained.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.